SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-349663
Filing Date
2021-12-07
Accepted
2021-12-07 08:01:56
Documents
14
Period of Report
2021-12-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d242231d8k.htm   iXBRL 8-K 30663
2 EX-99.1 d242231dex991.htm EX-99.1 20145
6 GRAPHIC g242231dsp01.jpg GRAPHIC 7299
  Complete submission text file 0001193125-21-349663.txt   192605

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aeri-20211206.xsd EX-101.SCH 2900
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeri-20211206_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeri-20211206_pre.xml EX-101.PRE 11413
7 EXTRACTED XBRL INSTANCE DOCUMENT d242231d8k_htm.xml XML 3410
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 211474703
SIC: 2836 Biological Products, (No Diagnostic Substances)